The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Incyte Corporation

  • INCY
  • NASDAQ
  • Consumer Products
  • Latest 44.54
  • Currency US$
  • Change 0.56
  • Percent Change 1.273 %
  • Volume 3,681,855
  • Thu Apr 17, 2014 04:00 PM EDT NASDAQ data delayed 15 minutes.
  • Open 43.95
  • Previous Close 44.54
  • High 46.15
  • Low 42.94
  • Bidx0 0.0000
  • Askx0 0.0000
  • 52-week High02/26 70.86
  • 52-week Low06/24 18.23
  • Beta 0.792
  • Market Cap 7,176.28M
  • EPS -0.56
  • P/E
  • Forward P/E 131.00
  • PEG
  • Annual Dividend 0.0000
  • Yield

News

Financials & Calendars

Income Statement

  • Sales $354,950,000
  • Earnings $-83,150,000
  • Return on Equity n/a

Cash Flow

  • Cash Flow --
  • Cash $471,420,000
  • Current Ratio 5.14

12 months ended Dec 31, 2013.

Trailing 12 month results shown above.
All data is in U.S. dollars.

Balance Sheet

  • Assets $629,560,000
  • Liabilities $822,670,000
  • Liabilities-to-Equity Ratio n/a

Price Ratios

  • Price to Sales 20.22
  • Price to Book n/a
  • Price to Cash Flow n/a

Event Calendar

Event Last   Next  
Earnings Feb 12 $-0.09 May 1 $-0.17
Surprises Feb 12 66.67% n/a n/a
Dividends n/a n/a n/a n/a
Splits n/a -- n/a n/a

12 months ended Apr 18, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

Incyte Corp is a drug discovery company that is using its expertise in genomics, medicinal chemistry and molecular, cellular and in vivo biology to discover and develop novel therapeutics. The company has three fully-staffed drug discovery programs underway focused primarily on the identification of new small molecule drugs for cancer and inflammation. Incyte also has strategic alliances with Lexicon Genetics and Medarex focused on the discovery and development of protein therapeutics or antibodies to treat inflammatory diseases and cancer.

Related Securities
Symbol Type Latest % Chg

Officers

  • Richard U. De Schutter Chairman
  • Herve Hoppenot Chief Executive Officer
  • Company Type: n/a
  • Company Status: n/a
  • Full-time Employees: n/a
  • Incorporation: United States,
    n/a
  • Top 1000 Ranking: Profit: n/a
    Revenue: n/a
    Assets: n/a

Head Office

ROUTE 141 & HENRY CLAY ROAD B
WILMINGTON, DE
19880

Phone: (302)-498-6700
Fax: (302)-4252750

pmurphy@incyte.com
www.incyte.com

Ideas & Discussion

Live Discussion of INCY on StockTwits